Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234962 · ClinicalTrials.gov registry record · Phase 4
Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy
A Phase 4 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT00234962 is a Phase 4 study that was terminated before completion, run by Abbott. The registered enrollment target is 200 participants.
The verdict
NCT00234962, a Phase 4 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of adherence on HIV antiviral response to treatment regimens containing Kaletra or other HIV protease inhibitors.
Interventions
- DRUG Lopinavir/Ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2002-08 |
| Est. Completion | 2007-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00234962
The ClinicalTrials.gov registry entry for NCT00234962 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lopinavir/Ritonavir is the first listed.
NCT00234962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00234962 about?
NCT00234962 is a clinical study titled "Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy". The purpose of this study is to evaluate the effects of adherence on HIV antiviral response to treatment regimens containing Kaletra or other HIV protease inhibitors.
What is the current status of trial NCT00234962?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2002-08. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00234962?
The interventions under investigation include: Lopinavir/Ritonavir (DRUG).
Who is sponsoring clinical trial NCT00234962?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.